hedge funds and digital health

“Comparing traditional pharma with digital health sounds very similar to comparing hedge funds to VC funds”


This weekend, I had brunch with a friend that runs her own hedge fund, and between eggs Benedict and Caesars (it’s a Canadian thing), we talked shop.


As an ex-corporate VC (focused on digital health), I was intrigued with how similar her hedge fund model is to how traditional pharma operates, and how doing digital health within a larger pharma is more similar to a VC (versus hedge fund) mindset.


Here's what I mean:

🤔 Similar to pharma’s reliance on IP, secrecy is often part-and-parcel of a hedge fund - revealing details of your trading strategy is a big no-no given a fund’s zero-sum nature


🤔 Whether it’s a new algorithm to create alpha or spotting market inefficiencies, like pharma’s reliance on multifaceted science, the hedge fund approach is often extremely analytical


🤔 Similar to business decisions in pharma, hedge fund managers can dissect a trade and review quantitative data as inputs to make a decision


🤔 The drug discovery process is well defined and can be managed with a ‘waterfall’ approach, which is very similar to how successful hedge funds run their shop


🤔 Like in pharma, the hedge fund investment process is continuous, as go/no-go decisions and position sizing can be adjusted and mitigated in real-time


Conversely, the VC mindset differs from hedge funds and is closer to how we run digital health projects within larger pharmas:


💡 Open networks and networking are encouraged and are a large part of building a VC’s competitive advantage – it’s a positive-sum game where everybody introduces everybody to grow the pie together (e.g., less secrecy)


💡 It’s hard to pin down the ‘secret sauce’ of a successful VC – while high-level analytics are involved, there’s a lot of instinct and subjective judgement with choosing the right projects


💡 Most VC investments are experimental, using an agile methodology to quickly find a market fit and pivot as required before committing large sums of capital


💡 Unlike hedge funds, VCs operate in a world with little data – startups often have no revenues or profits to analyze and it’s often a subjective judgement about a person / team


What I find fascinating is that while there are different approaches and mindsets used in drug development versus investing in digital health, the overall likelihoods of success are similar – the likelihood for drug approval hovers at around 6-10% (depending on the therapeutic area) while ‘successful’ VC investments typically see 10% of their investments become a ‘blockbuster’, 80% of their investments fail and the remaining 10% of their investments chug along and do ‘ok’…


The key takeaway from these parallels?


Toronto remains the brunch capital of the world and a great spot for thought-provoking lazy-Sunday morning conversations.

Recent Posts

See All

Having worked at the intersection of digital and pharma since 2008 (before it was sexy), I've had the opportunity to engage many talented executives trying to bring digital into an often risk-averse a

“Why should we invest in a digital therapeutic when it will never come close to generating the revenue we make from our drug portfolio? Why not reinvest into R&D to find the next blockbuster drug, whi

“It’s been 3 years of strategizing, ideating and experimenting with very little impact - unfortunately, our digital health folks have lost some credibility with the rest of the business” This unfortun